BioNTech Shares Plunge as Pfizer Exits Stake

A seismic development has rocked BioNTech’s stock valuation following the complete divestment of Pfizer’s substantial shareholding. The long-standing pandemic partner executed an accelerated block trade, offloading its entire remaining position of 4.55 million shares overnight, sending the biotechnology firm’s equity into a tailspin. This dramatic separation raises critical questions about the strategic implications for the Mainz-based company’s future trajectory.

Amid the market turmoil triggered by Pfizer’s exit, BioNTech had previously released third-quarter 2025 financial results that presented a mixed performance picture. Revenue figures provided a positive surprise, with the company generating €1.52 billion, substantially exceeding market expectations. This outperformance was primarily driven by a significant payment received through Read more...